(Q38595360)

4 September 2017

title

Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs (English)

1 reference

chronic obstructive pulmonary disease

4 September 2017

main subject

1 reference

4

Ralph J Panos

1 reference

4 September 2017

1

Aaron M Mulhall

1 reference

4 September 2017

Christopher A Droege

2

1 reference

4 September 2017

Neil E Ernst

series ordinal

3

1 reference

4 September 2017

Muhammad A Zafar

series ordinal

5

1 reference

4 September 2017

language of work or name

English

0 references

publication date

30 September 2015

1 reference

Expert Opinion on Investigational Drugs

4 September 2017

published in

1 reference

4 September 2017

volume

24

1 reference

4 September 2017

issue

12

1 reference

4 September 2017

page(s)

1597-1611

1 reference

Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Phosphodiesterase inhibitors in the treatment of inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Advances in targeting cyclic nucleotide phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

PDE4 inhibitors in COPD--a more selective approach to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Efficacy of roflumilast in the COPD frequent exacerbator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Longitudinal changes in clinical outcomes in older patients with asthma, COPD and asthma-COPD overlap syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Phosphodiesterases as Drug Targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Effects of KF19514, a phosphodiesterase 4 and 1 Inhibitor, on bronchial inflammation and remodeling in a murine model of chronic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Discovery of a novel orally active PDE-4 inhibitor effective in an ovalbumin-induced asthma murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

The inhaled administration of KF19514, a phosphodiesterase 4 and 1 inhibitor, prevents antigen-induced lung inflammation in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

The in vivo efficacy and side effect pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long-acting β 2-adrenoceptor agonist in preclinical animal species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Effect of theophylline on diaphragmatic muscle function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

RAR and RXR modulation in cancer and metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1094054

10.1517/13543784.2015.1094054

21 January 2018

Identifiers

DOI

1 reference

release_ax7olswehrbjtpea2wtgrn6maq

4 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ax7olswehrbjtpea2wtgrn6maq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference